We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hikma Pharmaceuticals Plc | LSE:HIK | London | Ordinary Share | GB00B0LCW083 | ORD SHS 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-6.00 | -0.33% | 1,813.00 | 1,810.00 | 1,811.00 | 1,838.00 | 1,804.00 | 1,818.00 | 365,955 | 16:35:27 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 2.88B | 192M | 0.8685 | 20.85 | 4B |
TIDMHIK
RNS Number : 8766Z
Hikma Pharmaceuticals Plc
15 January 2020
1.1 Annex DTR3
Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons
All relevant boxes should be completed in block capital letters
State whether the notification relates to (i) a transaction notified in accordance with DTR 3.1.2 R, (ii) a disclosure made in accordance with LR 9.8.6R(1) or (iii) a disclosure made in accordance with section 793 of the Name of the Issuer: Companies Act (2006): 1. Hikma Pharmaceuticals PLC 2. DTR 3.1.2 R State whether notification relates to a person connected with a person discharging Name of person discharging managerial responsibilities/ managerial responsibilities/director: director named in 3 and Said Darwazah, Mazen Darwazah identify the connected person: 3. and Ali Al-Husry 4. Yes: Darhold Limited --------------------------------------- ---- ----------------------------------- Indicate whether the notification is in respect of a holding of the person referred to Description of shares (including in 3 or 4 above or in respect class), debentures or derivatives of a non-beneficial interest: or financial instruments Beneficial interest in Darhold relating to shares: 5. Limited 6. Ordinary Shares --------------------------------------- ---- ----------------------------------- Name of registered shareholders(s) and, if more than one, the State the nature of the number of shares held by transaction: each of them: Pledge of 2,345,000 Ordinary 7. EFG Bank 8. Shares in support of a loan --------------------------------------- ---- ----------------------------------- Percentage of issued class acquired (treasury shares Number of shares, debentures of that class should not or financial instruments be taken into account when relating to shares acquired: calculating percentage): 9. None 10. N/A --------------------------------------- ---- ----------------------------------- Percentage of issued class disposed (treasury shares Number of shares, debentures of that class should not or financial instruments be taken into account when relating to shares disposed: calculating percentage): 11. None 12. N/A --------------------------------------- ---- ----------------------------------- Price per share or value of transaction: Date and place of transaction: 13. N/A 14. Amman, 15 January 2020 --------------------------------------- ---- ----------------------------------- Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account Date issuer informed of when calculating percentage): transaction: 15. 60,000,000 - 24.76 per cent. 16. 15 January 2020 --------------------------------------- ---- ----------------------------------- If a person discharging managerial responsibilities has been granted options by the issuer complete the following boxes ------------------------------------------------------------------------------ Period during which or date 17. Date of grant 18. on which exercisable --------------------------------- ---- ------------------------------- Total amount paid (if Description of shares or any) for grant of the debentures involved (class 19. option 20. and number) --------------------------------- ---- ------------------------------- Exercise price (if fixed at time of grant) or indication Total number of shares or that price is to be fixed debentures over which options 21. at the time of exercise 22. held following notification --------------------------------- ---- ------------------------------- Name of contact and telephone 23. Any additional information 24. number for queries --------------------------------- ---- ------------------------------- Name of authorised official or issuer responsible for making notification Peter Speirs, Company Secretary, Hikma Pharmaceuticals PLC Date of notification: 15 January 2020
Notes:
This form is intended for use by an issuer to make a RIS notification required by DTR 3.1.4
(1) An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24.
(2) An issuer making a notification in respect of a derivative relating the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24.
(3) An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24.
(4) An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
DSHGCGDBGSBDGGU
(END) Dow Jones Newswires
January 15, 2020 04:44 ET (09:44 GMT)
1 Year Hikma Pharmaceuticals Chart |
1 Month Hikma Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions